<DOC>
	<DOCNO>NCT01095601</DOCNO>
	<brief_summary>This study assess effect food pharmacokinetics avanafil ( Formulation II ) ; determine relative bioavailability two avanafil tablet formulation ( Formulation I versus Formulation II ) investigate dose-proportionality Formulation II avanafil tablet .</brief_summary>
	<brief_title>Assess Effect Food Avanafil Pharmacokinetic ( PK ) , Compare 2 Oral Formulations Avanafil , Investigate Dose Proportionality Healthy Male Subjects</brief_title>
	<detailed_description>In Phase I , single-centre , open-label , randomize , four-period crossover study , eligible subject randomize receive 4 treatment 4-way crossover fashion . The 4 treatment follow : - Treatment A : 2x100 mg Formulation II avanafil tablet , fast - Treatment B : 2x100 mg Formulation II avanafil tablet , feed - Treatment C : 2x100 mg Formulation I avanafil tablet , fast - Treatment D : 1x50 mg Formulation II avanafil tablet , fasted Subjects report study site evening treatment remain site 24-hour PK sample drawn . A single oral dose avanafil tablet administer 240 mL water . A washout period least 5 day occur treatment . Subjects treatment group A , C D fast least 10 hour prior least 4 hour follow dosing . Subjects treatment group B eat standardize high fat breakfast 30 prior dosing . Standard meal provide uniformly subject approximately 4 9 hour dose , even snack provide approximately 12 - 13 hour dose . Blood sample determination plasma avanafil metabolite concentration obtain subject 0 ( 30 minute pre-dose ) , 0.25 , 0.5 , 0.75 , 1 , 1.25 , 1.5 , 2 , 3 , 4 , 8 , 12 , 18 24 hour post-dose treatment period . Adverse event ; laboratory evaluation ; color vision test ( Treatment A ) , electrocardiogram physical examination , vital sign assess various time study .</detailed_description>
	<criteria>adult male subject , 18 45 year age , must medically healthy clinically significant screen result . history clinical evidence clinically relevant cardiovascular ( include thromboembolic disorder ) , hepatic , renal , hematological , endocrine , pulmonary , gastrointestinal , psychiatric neurological impairment ; clinically significant laboratory abnormality judge Investigator ; systolic blood pressure &lt; 90 &gt; 150 mmHg ; diastolic blood pressure &lt; 50 &gt; 95 mmHg ; history retinitis pigmentosa nonarteritic anterior ischemic optic neuropathy ; allergy previous adverse event PDE5 inhibitor constituent ; use prescription overthecounter drug know interfere metabolism cytochrome P450 3A4 enzyme within 30 day prior Day 1 Period 1 ; use investigational drug within 30 day six halflives , whichever longer , prior Day 1 Period 1 ; use prescription overthecounter drug herbal remedy within 14 day prior Day 1 Period 1 ; history alcohol drug abuse within 18 month , history smoking within 6 month ; positive urine alcohol test ; positive cotinine test , positive urine drug screen ; positive serology HIV , HCV antibody , HBsAg .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>avanafil</keyword>
	<keyword>absoprion</keyword>
	<keyword>bioavailability</keyword>
	<keyword>food effect</keyword>
	<keyword>dose-proportionality</keyword>
	<keyword>TA-1790</keyword>
	<keyword>Pharmacokinetics avanafil</keyword>
</DOC>